JP6957448B2 - ワクチン組成物およびその使用 - Google Patents

ワクチン組成物およびその使用 Download PDF

Info

Publication number
JP6957448B2
JP6957448B2 JP2018505505A JP2018505505A JP6957448B2 JP 6957448 B2 JP6957448 B2 JP 6957448B2 JP 2018505505 A JP2018505505 A JP 2018505505A JP 2018505505 A JP2018505505 A JP 2018505505A JP 6957448 B2 JP6957448 B2 JP 6957448B2
Authority
JP
Japan
Prior art keywords
crm
fusion peptide
seq
peptide
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018505505A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511659A (ja
JP2018511659A5 (enExample
Inventor
ウルスラ、ウィーデルマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolife Science QLD Ltd
Original Assignee
Biolife Science QLD Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015901375A external-priority patent/AU2015901375A0/en
Application filed by Biolife Science QLD Ltd filed Critical Biolife Science QLD Ltd
Publication of JP2018511659A publication Critical patent/JP2018511659A/ja
Publication of JP2018511659A5 publication Critical patent/JP2018511659A5/ja
Application granted granted Critical
Publication of JP6957448B2 publication Critical patent/JP6957448B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018505505A 2015-04-17 2016-04-15 ワクチン組成物およびその使用 Active JP6957448B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015901375A AU2015901375A0 (en) 2015-04-17 A vaccine composition and uses thereof
AU2015901375 2015-04-17
PCT/AU2016/050275 WO2016164980A1 (en) 2015-04-17 2016-04-15 A vaccine composition and uses thereof

Publications (3)

Publication Number Publication Date
JP2018511659A JP2018511659A (ja) 2018-04-26
JP2018511659A5 JP2018511659A5 (enExample) 2019-05-23
JP6957448B2 true JP6957448B2 (ja) 2021-11-02

Family

ID=57125491

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018505505A Active JP6957448B2 (ja) 2015-04-17 2016-04-15 ワクチン組成物およびその使用

Country Status (13)

Country Link
US (1) US10532090B2 (enExample)
EP (1) EP3283105B1 (enExample)
JP (1) JP6957448B2 (enExample)
KR (1) KR102372615B1 (enExample)
CN (1) CN108025061B (enExample)
AU (1) AU2016250289B2 (enExample)
ES (1) ES2908071T3 (enExample)
NZ (1) NZ736194A (enExample)
RS (1) RS63080B1 (enExample)
RU (1) RU2726411C2 (enExample)
SG (1) SG11201708247XA (enExample)
TW (1) TWI740823B (enExample)
WO (1) WO2016164980A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210346484A1 (en) * 2017-12-11 2021-11-11 Medizinische Universitaet Wien Method of producing a vaccine composition and uses thereof
CA3090552A1 (en) * 2018-02-07 2019-08-15 Imugene Limited A vaccine composition and uses thereof
WO2022133447A1 (en) * 2020-12-16 2022-06-23 Dynavax Technologies Corporation Method for quantifying cpg-containing oligonucleotides in formulations comprising alum

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0739984A1 (en) * 1995-04-26 1996-10-30 San Tumorforschungs-Gmbh Bivalent polypeptides containing at least two domains
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
JP4658423B2 (ja) * 1999-08-03 2011-03-23 ザ オハイオ ステイト ユニバーシティ Ｈｅｒ−２タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド
EP1236740B1 (de) 2001-02-28 2012-07-18 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. Vakzine gegen Krebserkrankungen, die mit dem HER-2/neu Onkogen assoziiert sind
WO2005021710A2 (en) * 2003-06-02 2005-03-10 University Of Miami Chimeric molecules and methods of use
EP1844788B1 (en) 2006-04-13 2010-07-14 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. HER-2/neu multi-peptide vaccine
EP2292258A1 (en) * 2009-08-18 2011-03-09 Pevion Biotech Ltd. Multiepitope vaccine for Her2/neu-associated cancers
EP2659906A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
ES2528109T3 (es) * 2012-05-31 2015-02-04 Innavirvax Compuestos inmunogénicos que comprenden péptido gp41 de VIH acoplado a proteína portadora CRM197
EP3166646A4 (en) * 2014-07-07 2018-03-07 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same

Also Published As

Publication number Publication date
US10532090B2 (en) 2020-01-14
EP3283105A1 (en) 2018-02-21
CN108025061A (zh) 2018-05-11
TW201705978A (zh) 2017-02-16
EP3283105A4 (en) 2018-12-19
JP2018511659A (ja) 2018-04-26
SG11201708247XA (en) 2017-11-29
KR20180003560A (ko) 2018-01-09
RU2017137502A3 (enExample) 2019-09-16
KR102372615B1 (ko) 2022-03-08
RS63080B1 (sr) 2022-04-29
CN108025061B (zh) 2022-02-15
AU2016250289B2 (en) 2017-03-02
US20170119867A1 (en) 2017-05-04
RU2726411C2 (ru) 2020-07-14
BR112017021981A2 (pt) 2018-07-10
HK1248536A1 (zh) 2018-10-19
TWI740823B (zh) 2021-10-01
NZ736194A (en) 2022-08-26
EP3283105B1 (en) 2022-01-26
ES2908071T3 (es) 2022-04-27
RU2017137502A (ru) 2019-05-17
AU2016250289A1 (en) 2017-01-05
WO2016164980A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
Ladjemi et al. Anti-HER2 vaccines: new prospects for breast cancer therapy
US10166276B2 (en) Compositions and methods for treatment of non-hodgkins lymphoma
CN105085684B (zh) Pcsk9靶向重组疫苗设计及其应用
JP6957448B2 (ja) ワクチン組成物およびその使用
CN112203681B (zh) 疫苗组合物及其用途
CN112771159A (zh) 精氨酸酶1多肽
AU2014296038B2 (en) Compositions for and methods of treating and preventing cancer targeting tumor associated carbohydrate antigens
US20180264093A1 (en) Immunogenic glycopeptide compounds, pharmaceutical compositions and uses thereof
US20210346484A1 (en) Method of producing a vaccine composition and uses thereof
US11154599B2 (en) Her2/neu immunogenic composition
HK1248536B (en) A vaccine composition and uses thereof
BR112017021981B1 (pt) Composição de vacina e usos da mesma
JP2018520152A (ja) 免疫原性プレプロカルシトニンペプチド
Dakappagari Evaluation of chimeric B-cell epitope vaccines of HER-2: application to cancer patients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190409

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210901

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210914

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211006

R150 Certificate of patent or registration of utility model

Ref document number: 6957448

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250